Khan warns that repeatedly replicating stem cells is not automatically beneficial. He says excessive passages can damage DNA, reduce stability and survival, and leave senescent cells that emit pro-inflammatory signals, making manufacturing details central to safety.

Passage count means how many times cells are replicated
Too many passages may cause DNA damage
Over-replicated cells may become unstable or senescent
Manufacturing quality can change the risk profile

“So, the times the number of times you replicate the stem cells, for example, if you replicate them too many times, it can cause DNA…”
Dr. Adeel Khan · 38:00

“So, then they can actually cause more harm potentially.”
Dr. Adeel Khan · 38:00

#stem cells#manufacturing#safety

Myth Buster55:30

Why Khan Questions IV NAD Without Trimethylglycine

Khan agrees that NAD supports mitochondrial processes but questions whether intravenous NAD reliably enters cells. He says clinics using IV NAD should understand trimethylglycine, which he claims can improve intracellular penetration and reduce symptoms such as nausea; these are his clinical views, not a general prescription.

NAD levels decline with age
Khan says IV NAD may remain outside cells
He links extracellular NAD with inflammation and nausea
He recommends asking whether a clinic uses trimethylglycine

“IV NAD may not actually do what is kind of touted to do and promoted to do. And it may actually cause more harm because…”
Dr. Adeel Khan · 56:00

“if you give it with NAD like 30 minutes before, then it can increase the intracellular penetration of NAD.”
Dr. Adeel Khan · 56:30

#nad#trimethylglycine#mitochondria

Hot Take· 1

Hot Take08:00

Why Khan Expects Regenerative Treatments to Get Cheaper

Using Tesla's early Roadster as an analogy, Khan argues that expensive early adopters can fund demand, manufacturing improvements, and eventual access. He predicts regenerative therapies could cost a fraction of today's prices within a decade, while noting that they currently remain expensive.

New technologies often begin as costly products for early adopters
Higher demand and manufacturing innovation can reduce prices
Khan says treatment prices have already declined over five years

“But the only way that's going to happen is unfortunately the famous and the rich have to do it first and then it'll trickle down…”
Dr. Adeel Khan · 08:30

“I feel like in 10 years this stuff will be a quarter of the price if not even potentially even less than that than it…”
Dr. Adeel Khan · 09:00

#cost curve#medical technology#access

Explainer· 6

Explainer03:00

Regenerative Medicine Tries to Repair, Not Just Manage

Khan defines regenerative medicine as an attempt to restore damaged tissue rather than remove it or manage symptoms with medication. He argues that the field is beginning to deliver real clinical applications after decades of promise.

The goal is to repair tissue toward its prior state
The approach contrasts with surgery and symptom-management drugs
Khan says clinical use is only at an early stage

“Yeah, it's it's an old term that came about because it was this whole idea that we can repair or fix tissue back to the…”
Dr. Adeel Khan · 03:00

“We're just trained that you can only manage symptoms and that you can't actually reverse disease.”
Dr. Adeel Khan · 03:30

#regenerative medicine#tissue repair#healthcare

Explainer05:00

Why Medical Research Can Take Decades to Reach Clinics

Khan describes a translational gap between findings in research and their adoption by average clinicians. He says regenerative medicine education is largely absent from medical-school curricula, leaving clinical practice behind rapidly developing science.

Research findings may take 15 to 20 years to reach routine care
Many doctors receive no formal regenerative-medicine curriculum
Public education can expose patients to options their doctors may not know

“shown in research to be effective gets translated into the clinics of the average doctor. So, there's a huge gap and delay and that's the…”
Dr. Adeel Khan · 05:30

“We didn't have a regenerative medicine curriculum in medical school and there still isn't a regenerative medicine curriculum.”
Dr. Adeel Khan · 05:30

#translational gap#medical education#clinical adoption

Explainer11:30

How Khan Says Follistatin Gene Therapy Extends Delivery

Khan says ordinary follistatin clears from the body quickly, making repeated dosing impractical. He describes a delivery system intended to make a patient's cells produce follistatin for 18 to 24 months, while acknowledging that benefits cannot be guaranteed and repeat treatment is eventually required.

Follistatin has a short half-life when injected conventionally
The described gene therapy uses one injection
Khan says expression lasts roughly 18 to 24 months
The treatment is not permanent and outcomes are not guaranteed

“that's our technology which allows us to insert any gene of interest into your body with one injection via subcutaneous injection in the fat or…”
Dr. Adeel Khan · 12:00

“produce Follistatin and then it just goes into your blood and then Follistatin does what it does, which is it increases energy, it increases strength,…”
Dr. Adeel Khan · 13:00

#follistatin#gene therapy#delivery

Explainer17:00

The City Analogy for Stem-Cell Exhaustion

Khan compares the body to a city whose DNA is stored in a central library and whose stem cells act as repair workers. In his analogy, aging reduces the repair workforce, allowing damage and faulty instructions to accumulate across tissues.

DNA is compared with a library of maintenance instructions
Stem cells act like repair and construction workers
Stem-cell exhaustion is presented as a hallmark of aging
Accumulated damage is linked to chronic disease risk

“Your body is like a city and imagine there's like different districts and there's there's this kind of golden library where it houses all the…”
Dr. Adeel Khan · 17:00

“But unfortunately, over time as you get older your stem cells get exhausted. That's one of the hallmarks of aging. It's called stem cell exhaustion.”
Dr. Adeel Khan · 17:30

#stem cells#aging#analogy

Explainer21:00

The Biggest Cell-Therapy Hurdle Is Staying in the Body

Khan says many intravenously delivered stem cells become trapped in the lungs, while tiny exosomes can distribute more widely. He identifies rapid immune clearance as a central technical problem and describes cloaking mechanisms and hydrogels as attempts to keep therapies active for longer.

Many intravenous stem cells become trapped in the lungs
Exosomes are small enough to travel more widely
The immune system can clear cells and exosomes quickly
Cloaking and hydrogel approaches aim to extend persistence

“the problem is when you do IV stem cells, most of them actually get trapped in the lungs.”
Dr. Adeel Khan · 21:00

#cell therapy#exosomes#immune clearance

Explainer45:00

The Mitochondrial Theory Behind Khan's SS-31 Interest

Khan presents mitochondria as regulators of energy, oxidative stress, and tissue homeostasis rather than mere cellular powerhouses. He argues that mitochondrial dysfunction may be a root driver of aging and names SS-31 as his preferred mitochondrial peptide, though the discussion does not establish it as standard care.

Mitochondria regulate more than energy production
Tissue homeostasis is the maintenance of a stable bodily state
Oxidative stress and antioxidant balance affect cellular damage
Khan says SS-31 may help restore mitochondrial function

“there's something called the unitary theory of aging. It's it's kind of this whole idea that there's one root cause of aging and it seems…”
Dr. Adeel Khan · 45:00

“So, SS-31 is probably my favorite mitochondrial peptide. And the reason is cuz they can help to restore mitochondrial function and help with the actual…”
Dr. Adeel Khan · 46:30

#mitochondria#ss-31#aging

Story· 1

Story1:00:30

Why Eterna Plans Few Clinics but More Biotech Products

Khan describes a business model built around a small number of destination clinics rather than a large franchise network. He expects the longer-term company to focus more heavily on biotech development and distribution, with clinics serving as exclusive medical-tourism locations.

The plan is five to ten clinics over five to ten years
Clinics are designed as destination locations
Expensive treatments reduce the need for a dense network
Biotech products and distribution are the longer-term focus

“my vision for the company is to be more of a biotech and distribution company over time but probably over the next 5 to 10…”
Dr. Adeel Khan · 1:00:30

“the idea is for them to be places where people go as a as almost like a destination every year or 2 years or whatever…”
Dr. Adeel Khan · 1:01:00

#biotech#business model#medical tourism

Takeaway· 1

Takeaway13:00

Biomarkers Matter Less Than What Changes for the Patient

Khan discusses biological-age tests but says clinical function matters more than a disputed biomarker. He looks for changes such as measurable muscle gain, energy, and strength rather than treating a clock score as the final outcome.

Chronological and measured biological age can differ
Khan says current biological-age tests are imperfect
DEXA scans can provide a concrete body-composition measure
Patient energy and strength are central clinical outcomes

“There's arguably there's not a great test for that at this moment, although there's a company out of Harvard called Generation Lab that measures biological…”
Dr. Adeel Khan · 13:00

“but to me what's most important is what's it actually doing to my patient.”
Dr. Adeel Khan · 14:00

#biomarkers#biological age#patient outcomes

Frameworks in this episode

Regenerative Provider Credibility Triage

Regenerative Treatment Matching Ladder

Insights & moments

⚡Myth Buster· 2

More Stem-Cell Replication Can Make a Product Worse